Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
Telix Announces First Patient Dosed in First-in-Human ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma 2025-04-02 03:30
FDA Approves New Prostate Cancer Imaging Agent Gozellix® 2025-03-21 08:38
Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America 2025-03-18 06:52
Telix Adds Lead-212 Isotope Production Capability 2025-03-13 06:48
Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum 2025-03-04 05:58
FDA Accepts BLA for TLX250-CDx (Zircaix®) for Kidney Cancer Imaging, Grants Priority Review 2025-02-26 08:49
Telix 2024 Full Year Results: Record Financial Performance and Investment in Future Growth, FY2025 Guidance of up to $1.23 Billion 2025-02-20 20:23
Illuccix® Approved in the United Kingdom 2025-02-13 05:30
Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform 2025-01-31 06:01
Telix Completes Acquisition of RLS (USA) Inc. 2025-01-28 05:40
Illuccix® Receives European Approval 2025-01-17 06:14
Telix Presentation to the 43rd Annual J.P. Morgan Healthcare Conference 2025-01-14 05:43
Telix Exceeds FY24 Guidance with US$142M Q4 Revenue 2025-01-13 15:12
Scintimun® Commercialization Partnership with Curium Pharma 2025-01-13 13:08
Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform 2025-01-13 06:34
NOBLE Registry Update: TLX599-CDx PSMA SPECT Imaging of Prostate Cancer Published in EJNMMI Reports 2024-12-31 04:45
Telix Files TLX250-CDx (Zircaix®) BLA for Kidney Cancer Imaging 2024-12-30 06:00
Telix Manufacturing Solutions, Brussels South Update: Cyclotron Installation Complete 2024-12-19 17:02
First Patient Dosed in Phase III ZIRCON-CP Trial of TLX250-CDx for Kidney Cancer Imaging in Chinese Patients 2024-11-28 17:22
Telix to Add FAP-Targeting Candidates to Theranostic Pipeline 2024-11-19 06:24
1 2 3 4 5 9